Back to Journals » Cancer Management and Research » Volume 5
Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
Authors Chao MP
Received 24 April 2013
Accepted for publication 10 June 2013
Published 23 August 2013 Volume 2013:5 Pages 251—269
DOI https://doi.org/10.2147/CMAR.S34273
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Mark P Chao
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA
Abstract: Over the last few decades, advances in immunochemotherapy have led to dramatic improvement in the prognosis of non-Hodgkin’s lymphoma (NHL). Despite these advances, relapsed and refractory disease represents a major treatment challenge. For both aggressive and indolent subtypes of NHL, there is no standard of care for salvage regimens, with prognosis after relapse remaining relatively poor. Nevertheless, there are multiple emerging classes of targeted therapies for relapsed/refractory disease, including monoclonal antibodies, antibody–drug conjugates, radioimmunotherapy, small-molecule inhibitors of cell-growth pathways, and novel chemotherapy agents. This review will discuss treatment challenges of NHL, current available salvage regimens for relapsed/refractory NHL, and the safety and efficacy of novel emerging therapies.
Keywords: non-Hodgkin’s lymphoma, relapsed/refractory disease, novel therapies
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.